TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10790936

Group type: EXPERIMENTAL
Intervention: Breast Cancer Patients' Needs Questionnaire (BR-CPNQ)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Rural women
Number of subjects: 334
Study: 8836789

Group type: EXPERIMENTAL
Intervention: Epirubicin therapy (50 mg diluted in 50 ml saline, installed weekly for 8 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (TUR alone)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Epirubicin therapy
Number of subjects: 45
Study: 1948212

Group type: EXPERIMENTAL
Intervention: Heart Smart Family Health Promotion Program (12-week program focused on eating, exercise, and smoking behavior changes)
Number of subjects: 42
Study: 6437365

Group type: EXPERIMENTAL
Intervention: 5 mg of fluphenazine decanoate every two weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: 25 mg of fluphenazine decanoate every two weeks
Number of subjects: 50
Study: 30308558

Group type: EXPERIMENTAL
Intervention: Ocriplasmin (single intravitreal injection)
Number of subjects: 466
Study: 30305255

Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavior therapy (iCBT)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: self-assessed cardiac-related fear
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sex
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: number of words used in the first homework assignment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: random forest model
Number of subjects: 90
Study: 26771268

Group type: EXPERIMENTAL
Intervention: Ketamine (0.3 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiologic solution (control)
Number of subjects: 80
Study: 25879722

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS) + Conventional Medical Management (CMM)
Number of subjects: 80
Study: 21822630

Group type: EXPERIMENTAL
Intervention: KiVa anti-bullying program
Number of subjects: 7741

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7741
Study: 19968743

Group type: EXPERIMENTAL
Intervention: Modified tunnel/connective tissue graft (CTG) technique with enamel matrix derivative (EMD)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Modified tunnel/connective tissue graft (CTG) technique alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 20
Study: 18356607

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM)
Number of subjects: 104
Study: 16043723

Group type: EXPERIMENTAL
Intervention: Subcutaneous lispro (0.15 units/kg every 2 h)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuous intravenous regular insulin (0.1 unit x kg(‐1) x h(‐1); CIRI group)
Number of subjects: 60
Study: 12454764

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (12+/‐1 g day(‐1))
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 23
Study: 10084268

Group type: EXPERIMENTAL
Intervention: Patients with open-angle glaucoma (treated IOP > 21 mmHg)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Patients with open-angle glaucoma (progression despite IOP < 21 mmHg)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Patients with normal-tension glaucoma
Number of subjects: 474

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 474
Study: 8721940

Group type: EXPERIMENTAL
Intervention: Ginseng 100 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ginseng 200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1783249

Group type: EXPERIMENTAL
Intervention: Inflammatory bowel disease patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Evolutive colitis group
Number of subjects: 17
Study: 6655414

Group type: EXPERIMENTAL
Intervention: Class teaching breast self-examination (BSE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women in a different district)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-attenders
Number of subjects: 0
Study: 30632018

Group type: EXPERIMENTAL
Intervention: Genomic BAC library construction and analysis of ZW-derived BAC clones
Number of subjects: 200448

Group type: EXPERIMENTAL
Intervention: BAC library screening using a ZW-specific marker
Number of subjects: 200448

Group type: EXPERIMENTAL
Intervention: Sequencing of selected BAC clones (P331M17 and P122G2)
Number of subjects: 200448
Study: 29883497

Group type: EXPERIMENTAL
Intervention: ramipril (maximum dose 10 mg depending on blood pressure) for 24±6 weeks
Number of subjects: 63

Group type: COMPARATOR
Intervention: placebo for 24±6 weeks
Number of subjects: 63
Study: 27998854

Group type: EXPERIMENTAL
Intervention: Early active antihypertensive treatment with SBP control target of 130‐140 mm Hg
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment with SBP control target of 170‐180 mm Hg
Number of subjects: 102
Study: 25270886

Group type: EXPERIMENTAL
Intervention: Active website (Group 1)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Active website with telephone (Group 2)
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Active website with email (Group 3)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control (Group 4)
Number of subjects: 558

Group type: COMPARATOR
Intervention: Control with telephone (Group 5)
Number of subjects: 558
Study: 22083325

Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site varicocele ligation (LESS-VL)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Conventional transperitoneal laparoscopic varicocele ligation (CTL-VL)
Number of subjects: 82
Study: 19327258

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 21747350

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy with sapheno-femoral junction ligation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard stripping surgery
Number of subjects: 60
Study: 16046308

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day)
Number of subjects: 3234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study: 11826416

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 10365734

Group type: EXPERIMENTAL
Intervention: Oral estradiol valerate combined with micronized progesterone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol combined with micronized progesterone
Number of subjects: 37

Group type: COMPARATOR
Intervention: No hormonal treatment
Number of subjects: 37
Study: 7497717

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia/epidural opiate analgesia (regional anesthesia)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia/intravenous patient‐controlled analgesia (general anesthesia)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study: 2042443

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg, b.i.d., for 60 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 6794585

Group type: EXPERIMENTAL
Intervention: Warm, humidified air
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 85
Study: 31468528

Group type: EXPERIMENTAL
Intervention: Web-based Acceptance and Commitment Therapy (ACT) program
Number of subjects: 1162

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1162
Study: 30167045

Group type: EXPERIMENTAL
Intervention: 80mg/8ml intravenous phloroglucinol
Number of subjects: 122

Group type: COMPARATOR
Intervention: 8ml of sterile water (placebo)
Number of subjects: 122
Study: 27393928

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin 500 mg plus metronidazole 400 mg (3×/day, 7 days)
Number of subjects: 345

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 345

Group type: EXPERIMENTAL
Intervention: Adjunctive systemic amoxicillin plus metronidazole
Number of subjects: 345
Study: 24346594

Group type: EXPERIMENTAL
Intervention: High-dose inhaled beclomethasone (n = 86)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo (n = 99)
Number of subjects: 185
Study: 22435244

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP) based ART
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV) based ART
Number of subjects: 121

Group type: COMPARATOR
Intervention: Both NVP and EFV groups
Number of subjects: 121

Group type: COMPARATOR
Intervention: EFV group
Number of subjects: 121
Study: 19878037

Group type: EXPERIMENTAL
Intervention: Nitric oxide-liberating cream applied twice daily for 10 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily for 10 days
Number of subjects: 64
Study: 19189566

Group type: EXPERIMENTAL
Intervention: Antismoking counseling
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control activities
Number of subjects: 199
Study: 15668495

Group type: EXPERIMENTAL
Intervention: False-positive prostate cancer screening results
Number of subjects: 2290

Group type: COMPARATOR
Intervention: Negative prostate cancer screening results
Number of subjects: 2290
Study: 12912723

Group type: EXPERIMENTAL
Intervention: Argatroban (2 micro g/kg per minute, adjusted to maintain aPTT at 1.5 to 3 times baseline for 5 to 7 days)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: Argatroban
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control
Number of subjects: 418
Study: 10594402

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8607727

Group type: EXPERIMENTAL
Intervention: Leisure physical activity (moderate and heavy)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Leisure physical activity (heavy)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Leisure physical activity (highest intensity)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Home physical activity (heavy)
Number of subjects: 851

Group type: COMPARATOR
Intervention: Leisure, occupational, or home physical activity
Number of subjects: 851
Study: 1673210

Group type: EXPERIMENTAL
Intervention: Intensive fly control measures (bait and trap strategy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no fly control measures)
Number of subjects: 0
Study: 7277107

Group type: COMPARATOR
Intervention: Pooled breast milk (PBM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mother's own milk (PT)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infant formula (SMA24)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Infant formula (SMA20)
Number of subjects: 24
Study: 30559023

Group type: EXPERIMENTAL
Intervention: HIV-unexposed children
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HIV-exposed children
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: HIV-exposed infants
Number of subjects: 453
Study: 30546024

Group type: EXPERIMENTAL
Intervention: Participants aged 40-79 years
Number of subjects: 12013

Group type: EXPERIMENTAL
Intervention: Increasing age, male sex, and widowed marital status
Number of subjects: 12013

Group type: EXPERIMENTAL
Intervention: Residents aged 80 years and over
Number of subjects: 12013

Group type: EXPERIMENTAL
Intervention: Higher blood level of total cholesterol
Number of subjects: 12013

Group type: EXPERIMENTAL
Intervention: Female participants with lower level of high density lipoprotein cholesterol and higher level of uric acid
Number of subjects: 12013

Group type: EXPERIMENTAL
Intervention: Personal illness such as hypertension, diabetes mellitus, dyslipidemia, myocardial infarction, heart failure, stroke, and transient ischemic attack
Number of subjects: 12013
Study: 26506138

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 2% topical solution BID
Number of subjects: 260

Group type: COMPARATOR
Intervention: Vehicle control solution
Number of subjects: 260
Study: 24857600

Group type: EXPERIMENTAL
Intervention: Goal setting intervention
Number of subjects: 724
Study: 22240928

Group type: EXPERIMENTAL
Intervention: BWD+PHMB
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ag
Number of subjects: 38
Study: 19937367

Group type: EXPERIMENTAL
Intervention: BDNF expression in vestibular schwannomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of BDNF with Ki-67 labelling index
Number of subjects: 0

Group type: COMPARATOR
Intervention: Expression of other neurotrophic factors (artemin, GDNF)
Number of subjects: 0
Study: 18616586

Group type: EXPERIMENTAL
Intervention: Diet high in resistant starch (RS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diet high in nonstarch polysaccharides (NSP)
Number of subjects: 46
Study: 15807754

Group type: EXPERIMENTAL
Intervention: Written education
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Verbal education (in addition to written education)
Number of subjects: 245
Study: 12270990

Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional dialysate
Number of subjects: 30
Study: 9814743

Group type: COMPARATOR
Intervention: Routine consent only
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Routine consent with added verbal information
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Routine consent with added written information
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Routine consent with added written and verbal information
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 32
Study: 7645037

Group type: EXPERIMENTAL
Intervention: BT563 (murine IgG1 anti-IL-2R antibody)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: BT563
Number of subjects: 56
Study: 2650603

Group type: EXPERIMENTAL
Intervention: Nocturnal symptoms and hiatal hernia
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Heartburn at night
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Regurgitation
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 50
Study: 792789

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) (6 to 14 cm H2O)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (oxygen and mechanical ventilation if needed)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: PEEP
Number of subjects: 72
Study: 31664429

Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 29137160

Group type: EXPERIMENTAL
Intervention: Toothpaste with Australian Melaleuca alternifolia oil (TTO) and ethanolic extract of Polish propolis (EEP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control toothpaste without TTO and EEP
Number of subjects: 51
Study: 25828172

Group type: EXPERIMENTAL
Intervention: Cognitive existential couple therapy (CECT)
Number of subjects: 62
Study: 23328270

Group type: EXPERIMENTAL
Intervention: EZG 200 mg + ethanol 1 g/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ethanol 1 g/kg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: EZG 200 mg
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo + ethanol placebo
Number of subjects: 17
Study: 19520745

Group type: EXPERIMENTAL
Intervention: Reasoning training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 34
Study: 19447249

Group type: EXPERIMENTAL
Intervention: Sequential docetaxel after anthracycline chemotherapy (FEC for four cycles followed by docetaxel 100 mg/m2 for four cycles)
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Control regimen (FEC for eight cycles or epirubicin for four cycles followed by CMF for four cycles)
Number of subjects: 4162

Group type: EXPERIMENTAL
Intervention: Experimental group (sequential docetaxel)
Number of subjects: 4162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4162
Study: 17007812

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group intervention
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Expressive writing
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Journaling
Number of subjects: 225

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 225
Study: 14977675

Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 180

Group type: COMPARATOR
Intervention: Brace-only treatment
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Combination treatment
Number of subjects: 180
Study: 11345223

Group type: EXPERIMENTAL
Intervention: Ritonavir (600 mg twice daily)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Indinavir (800 mg 3 times daily)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Ritonavir/saquinavir (400 mg each twice daily)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Change in PI treatment
Number of subjects: 111
Study: 9696508

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoanalytically oriented therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioural therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy combined with imipramine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maintenance therapy with imipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy
Number of subjects: 0
Study: 8029809

Group type: EXPERIMENTAL
Intervention: Dermatan sulphate (DS)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Heparin (H)
Number of subjects: 10
Study: 2809693

Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg b.i.d. for 10 to 11 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cefaclor 500 mg t.i.d. for 10 to 11 days
Number of subjects: 30
Study: 4573315

Group type: EXPERIMENTAL
Intervention: Phenformin and ethyloestrenol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Phenformin and stanozolol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30849250

Group type: EXPERIMENTAL
Intervention: Remifentanil patient‐controlled intravenous labor analgesia (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Patient‐controlled epidural analgesia (PCEA) (Group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spontaneous labor (Group C)
Number of subjects: 120
Study: 31336570

Group type: EXPERIMENTAL
Intervention: Fermented milk containing 40 billion of Lactobacillus casei Shirota (LcS) per day (LcS group, n = 20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (unfermented milk, n = 22)
Number of subjects: 42
Study: 27966237

Group type: EXPERIMENTAL
Intervention: Rilotumumab (15 mg/kg), Epirubicin (50 mg/m2), Cisplatin (60 mg/m2), Capecitabine (625 mg/m2 twice daily)
Number of subjects: 609

Group type: EXPERIMENTAL
Intervention: Rilotumumab
Number of subjects: 609
Study: 25139606

Group type: EXPERIMENTAL
Intervention: Instructor feedback
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (no instructor feedback)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Both groups at follow-up
Number of subjects: 99
Study: 24225201

Group type: EXPERIMENTAL
Intervention: Ivabradine (2.5 to 7.5mg bid)
Number of subjects: 6505

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6505

Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6505
Study: 22168585

Group type: EXPERIMENTAL
Intervention: Team midwifery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caseload midwifery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 17828747

Group type: EXPERIMENTAL
Intervention: High-dose glucocorticoids (prednisone or dexamethasone)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Low dose ACTH (LD-ACTH) stimulation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Follow-up LD-ACTH testing
Number of subjects: 64
Study: 16796788

Group type: EXPERIMENTAL
Intervention: Panitumumab as a single agent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study: 11931063

Group type: EXPERIMENTAL
Intervention: Cramp finding positive preoperatively
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cramp finding positive postoperatively
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Cramp finding compared to SLR test
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Outcome evaluation
Number of subjects: 133
Study: 10078539

Group type: EXPERIMENTAL
Intervention: Sildenafil (25 mg, 3 times a day for 4 days) + glyceryl trinitrate (0.5 mg/mL infusion)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Sildenafil (100 mg) + amlodipine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo + amlodipine
Number of subjects: 2
Study: 7735024

Group type: EXPERIMENTAL
Intervention: Abrupt cessation
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Taper with placebo gum
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Taper with active gum
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 26
Study: 1708984

Group type: EXPERIMENTAL
Intervention: 7.5% sodium chloride in 6% dextran 70 (HSD)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Normal crystalloid solution (control)
Number of subjects: 422
Study: 7238015

Group type: EXPERIMENTAL
Intervention: 21-day patch testing method
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aluminum chamber method
Number of subjects: 5
Study: 6149491

Group type: EXPERIMENTAL
Intervention: Flurazepam 30 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (for both flurazepam and temazepam)
Number of subjects: 24
Study: 30891610

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with recombinant tissue plasminogen activator (alteplase)
Number of subjects: 242
Study: 30361675

Group type: EXPERIMENTAL
Intervention: Zein-ALA nanosphere formulation (F3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Marketed tablets
Number of subjects: 0
Study: 27806718

Group type: EXPERIMENTAL
Intervention: VR-based intervention using Reh@City for cognitive rehabilitation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: VR-based intervention
Number of subjects: 18